QQQ   341.10 (-1.01%)
AAPL   159.22 (-0.29%)
MSFT   299.84 (+1.05%)
FB   294.64 (+0.00%)
GOOGL   2,580.10 (-0.18%)
AMZN   2,792.75 (+0.55%)
TSLA   829.10 (-11.55%)
NVDA   219.44 (-3.64%)
BABA   111.79 (-1.39%)
NIO   21.11 (-6.84%)
AMD   102.60 (-7.33%)
CGC   6.85 (-5.26%)
MU   78.72 (-3.96%)
GE   89.90 (+0.65%)
T   24.12 (-0.54%)
F   19.55 (-1.81%)
DIS   135.42 (+1.36%)
AMC   14.52 (-8.91%)
PFE   53.37 (+0.68%)
ACB   3.79 (-6.65%)
BA   189.75 (-2.33%)
QQQ   341.10 (-1.01%)
AAPL   159.22 (-0.29%)
MSFT   299.84 (+1.05%)
FB   294.64 (+0.00%)
GOOGL   2,580.10 (-0.18%)
AMZN   2,792.75 (+0.55%)
TSLA   829.10 (-11.55%)
NVDA   219.44 (-3.64%)
BABA   111.79 (-1.39%)
NIO   21.11 (-6.84%)
AMD   102.60 (-7.33%)
CGC   6.85 (-5.26%)
MU   78.72 (-3.96%)
GE   89.90 (+0.65%)
T   24.12 (-0.54%)
F   19.55 (-1.81%)
DIS   135.42 (+1.36%)
AMC   14.52 (-8.91%)
PFE   53.37 (+0.68%)
ACB   3.79 (-6.65%)
BA   189.75 (-2.33%)
QQQ   341.10 (-1.01%)
AAPL   159.22 (-0.29%)
MSFT   299.84 (+1.05%)
FB   294.64 (+0.00%)
GOOGL   2,580.10 (-0.18%)
AMZN   2,792.75 (+0.55%)
TSLA   829.10 (-11.55%)
NVDA   219.44 (-3.64%)
BABA   111.79 (-1.39%)
NIO   21.11 (-6.84%)
AMD   102.60 (-7.33%)
CGC   6.85 (-5.26%)
MU   78.72 (-3.96%)
GE   89.90 (+0.65%)
T   24.12 (-0.54%)
F   19.55 (-1.81%)
DIS   135.42 (+1.36%)
AMC   14.52 (-8.91%)
PFE   53.37 (+0.68%)
ACB   3.79 (-6.65%)
BA   189.75 (-2.33%)
QQQ   341.10 (-1.01%)
AAPL   159.22 (-0.29%)
MSFT   299.84 (+1.05%)
FB   294.64 (+0.00%)
GOOGL   2,580.10 (-0.18%)
AMZN   2,792.75 (+0.55%)
TSLA   829.10 (-11.55%)
NVDA   219.44 (-3.64%)
BABA   111.79 (-1.39%)
NIO   21.11 (-6.84%)
AMD   102.60 (-7.33%)
CGC   6.85 (-5.26%)
MU   78.72 (-3.96%)
GE   89.90 (+0.65%)
T   24.12 (-0.54%)
F   19.55 (-1.81%)
DIS   135.42 (+1.36%)
AMC   14.52 (-8.91%)
PFE   53.37 (+0.68%)
ACB   3.79 (-6.65%)
BA   189.75 (-2.33%)
NYSE:AMAM

Ambrx Biopharma News Headlines

$4.98
-0.05 (-0.99%)
(As of 01/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.85
▼
$5.27
50-Day Range
$4.98
▼
$11.41
52-Week Range
$4.85
▼
$22.87
Volume
21,116 shs
Average Volume
25,673 shs
Market Capitalization
$187.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Get Ambrx Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMAM and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Ambrx Biopharma Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AMAM
News Sentiment
▼
0.99

0.29
▲
Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AMAM Articles
This Week
▼
2

1
▲
AMAM Articles
Average Week



Ambrx Biopharma (NYSE:AMAM) News Headlines Today

SourceHeadline
MarketBeat logoShort Interest in Ambrx Biopharma Inc. (NYSE:AMAM) Drops By 20.6%
americanbankingnews.com - January 20 at 1:52 PM
nasdaq.com logoAmbrx Biopharma Inc - ADR Shares Near 52-Week Low - Market Mover
nasdaq.com - January 14 at 6:34 PM
nasdaq.com logoAmbrx Biopharma Inc - ADR Shares Fall 0.3% Below Previous 52-Week Low - Market Mover
nasdaq.com - January 13 at 9:46 PM
nasdaq.com logoAmbrx Biopharma Inc - ADR Shares Close the Day 10.7% Lower - Daily Wrap
nasdaq.com - January 13 at 9:46 PM
nasdaq.com logoAmbrx Biopharma Inc - ADR Shares Fall 2.8% Below Previous 52-Week Low - Market Mover
nasdaq.com - January 13 at 12:53 AM
nasdaq.com logoAmbrx Biopharma Inc - ADR Shares Fall 2.1% Below Previous 52-Week Low - Market Mover
nasdaq.com - January 11 at 9:42 PM
nasdaq.com logoAmbrx Biopharma Inc - ADR Shares Fall 1.4% Below Previous 52-Week Low - Market Mover
nasdaq.com - January 7 at 11:15 PM
finance.yahoo.com logoAmbrx Biopharma (AMAM) Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - December 29 at 7:55 AM
nasdaq.com logoAmbrx Biopharma Inc - ADR Shares Close the Day 18.7% Higher - Daily Wrap
nasdaq.com - December 21 at 7:15 PM
nasdaq.com logoAmbrx Biopharma Inc - ADR Shares Close the Day 11.5% Higher - Daily Wrap
nasdaq.com - December 9 at 6:17 PM
markets.businessinsider.com logoAmbrx Biopharma Shares Jump After Safety, Efficacy Data From Breast Cancer Trial
markets.businessinsider.com - December 9 at 1:17 PM
finance.yahoo.com logoAmbrx Biopharma Inc. Presents Positive Data from Ongoing ACE-Breast-01 Phase 1 Clinical Study of ARX788 at San Antonio Breast Cancer Symposium
finance.yahoo.com - December 9 at 1:17 PM
nasdaq.com logoAmbrx Biopharma Inc - ADR Shares Fall 3.6% Below Previous 52-Week Low - Market Mover
nasdaq.com - December 6 at 8:20 PM
nasdaq.com logoAmbrx Biopharma Inc - ADR Shares Fall 2.9% Below Previous 52-Week Low - Market Mover
nasdaq.com - December 3 at 6:17 PM
nasdaq.com logoAmbrx Biopharma Inc - ADR Shares Fall 0.1% Below Previous 52-Week Low - Market Mover
nasdaq.com - December 2 at 8:14 PM
finance.yahoo.com logoAmbrx Biopharma Inc. Announces Acceptance of Two Poster Presentations at the 2021 San Antonio Breast Cancer Symposium
finance.yahoo.com - November 19 at 7:00 PM
nasdaq.com logoHow Much Of Ambrx Biopharma Inc. (NYSE:AMAM) Do Institutions Own?
nasdaq.com - November 8 at 12:25 PM
finance.yahoo.com logoWhat Type Of Shareholders Make Up Ambrx Biopharma Inc.'s (NYSE:AMAM) Share Registry?
finance.yahoo.com - November 8 at 7:24 AM
finance.yahoo.com logoAmbrx Biopharma Inc. Announces First Patient Dosed in its Global Phase 2 ACE-Breast-03 Clinical Study of ARX788 for the Treatment of HER2-Positive Metastatic Breast Cancer
finance.yahoo.com - November 4 at 2:45 PM
finance.yahoo.com logoAmbrx Biopharma Inc. to Present at the 30th Annual Virtual Credit Suisse Healthcare Conference
finance.yahoo.com - November 1 at 7:23 PM
finance.yahoo.com logoAmbrx Biopharma Inc. Reports 1H 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - October 28 at 8:18 PM
nasdaq.com logoAmbrx Biopharma Inc - ADR Shares Fall 1.3% Below Previous 52-Week Low - Market Mover
nasdaq.com - October 12 at 11:00 PM
markets.businessinsider.com logoBiotech Company Pasithea Offers Two-Pronged Approach in Psychiatric Treatment
markets.businessinsider.com - October 5 at 9:23 AM
finance.yahoo.com logoAmbrx Announces Positive Data on ARX788 for the Treatment of HER2+ Gastric Cancer Presented at CSCO
finance.yahoo.com - October 4 at 9:08 AM
finance.yahoo.com logoAmbrx to Participate in Panel Discussion at the H.C. Wainwright 23rd Annual Global Investment Conference
finance.yahoo.com - September 9 at 8:23 PM
finance.yahoo.com logoAmbrx Announces First Patient Dosed in a Phase 1 Trial for ARX517, an ADC in Development to Treat PSMA Expressing Tumors
finance.yahoo.com - August 3 at 9:11 AM
Get Ambrx Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMAM and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.